Dr George Goshua (Yale University School of Medicine, New Haven, CT, USA) shares with us his insights into the role of endotheliopathy in the development of coagulopathy in patients with COVID-19.
Questions:
1. How common is coagulopathy in COVID-19 infection and who is at greatest risk? (0:03)
2. What is known about the role of endotheliopathy in the development of coagulopathy in patients with COVID-19? (1:39)
3. What is the link between the inflammatory response to SARS-CoV-2 and endotheliopathy? (2:23)
4. What practical advice would you give to physicians managing coagulopathy in patients with COVID-19 in terms of laboratory monitoring and anticoagulant therapy management? (3:33)
5. What can be done to identify high-risk populations? (5:33)
Abstract LB2605, Endotheliopathy is Essential in COVID-19 Associated Coagulopathy, is available at EHA25 Virtual here.
Speaker disclosure: George Goshua has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media.
Filmed at the Virtual Edition of the 25th European Hematology Association Annual Congress (EHA25 Virtual), June 2020.
COVID-19 = coronavirus disease 2019; SARS CoV-2 = severe acute respiratory syndrome coronavirus 2.
